Verastem Inc. Reports Increased Operating Expenses and Net Loss

TipRanksNov 22 11:54

Byondis Appoints Louis Denis, M.D., as Chief Medical Officer

BusinesswireNov 19 14:11

RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $13

Futu NewsNov 7 20:31 · Ratings

A. G. P. Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14

Futu NewsNov 7 20:31 · Ratings

Express News | Corrected-Verastem Inc: Qtrly Adj Shr Loss $0.88 (Not '$0.71')

BreakingsNov 7 06:09

Verastem | 10-Q: Q3 2024 Earnings Report

SECNov 7 05:27 · Announcements